{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:38:46Z","timestamp":1759538326779,"version":"build-2065373602"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":256,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Aging populations and advances in medical care have contributed to an increase in the number of patients with Parkinson\u2019s disease and cancer survivors. However, the effects of Parkinson\u2019s disease on the survival of patients with cancer remain unclear. We aimed to investigate the effect of Parkinson\u2019s disease on the prognosis of patients with cancer. This retrospective multicentre cohort study used data from the Osaka Cancer Registry, which was linked to administrative data obtained between 2010 and 2015 in Japan. Patients with cancer who were followed up for 5 years after cancer diagnosis were categorized into Parkinson\u2019s disease and non- Parkinson\u2019s disease groups according to the presence of comorbid Parkinson\u2019s disease. We compared survival between the two groups using Kaplan\u2013Meier analyses. Cox proportional-hazard models were used to assess the hazard ratio and 95% confidence interval of Parkinson\u2019s disease for all-cause mortality. Propensity-score matching was used to validate the analysis and address differences in clinical characteristics between the groups. The cohort included 118 999 patients with cancer and 1049 patients (0.9%) with comorbid Parkinson\u2019s disease. The patients in the Parkinson\u2019s disease group were older and had lower mobility than those in the non- Parkinson\u2019s disease group. Kaplan\u2013Meier analysis revealed that the 5-year survival rate after cancer diagnosis was significantly worse in the Parkinson\u2019s disease group than in the non- Parkinson\u2019s disease group (54% versus 70%, P &amp;lt; 0.001). Comorbid Parkinson\u2019s disease was independently associated with 5-year mortality [crude hazard ratio (95% confidence interval), 1.72 (1.56\u20131.88), P &amp;lt; 0.001]. This association remained significant after adjusting for potential confounders [adjusted hazard ratio (95% confidence interval), 1.37 (1.25\u20131.51), P &amp;lt; 0.001]. When the survival analysis was stratified by mobility, no intergroup difference in prognosis was observed among patients with impaired mobility. However, among patients with independent mobility, patients in the Parkinson\u2019s disease group had a worse prognosis than those in the non- Parkinson\u2019s disease group [crude hazard ratio (95% confidence interval), 1.74 (1.42\u20132.13), P &amp;lt; 0.001]. Similar results were observed after propensity-score matching. Patients with cancer and comorbid Parkinson\u2019s disease had a worse prognosis than those without comorbid Parkinson\u2019s disease. The effect varied depending on mobility. These findings highlight the importance of carefully managing Parkinson\u2019s disease symptoms and maintaining mobility in cancer patients with Parkinson\u2019s disease, as this could potentially improve their prognosis and survival outcomes.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf347","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:28:30Z","timestamp":1758310110000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of Parkinson\u2019s disease on survival in cancer survivors: a retrospective, multicentre cohort study in Japan"],"prefix":"10.1093","volume":"7","author":[{"given":"Kanako","family":"Asai","sequence":"first","affiliation":[{"name":"Department of Neurology, Osaka University Graduate School of Medicine , Suita, Osaka 565-0871 ,","place":["Japan"]},{"name":"Cancer Control Center, Osaka International Cancer Institute , Osaka-shi, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Gon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Osaka University Graduate School of Medicine , Suita, Osaka 565-0871 ,","place":["Japan"]},{"name":"Cancer Control Center, Osaka International Cancer Institute , Osaka-shi, Osaka 541-8567 ,","place":["Japan"]},{"name":"Department of Medical Innovation, Academic Clinical Research Center, Osaka University Hospital , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Osaka University Graduate School of Medicine , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Morishima","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , Osaka-shi, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-7542","authenticated-orcid":false,"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Osaka University Graduate School of Medicine , Suita, Osaka 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Miyashiro","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , Osaka-shi, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"issue":"9996","key":"2025100309090705900_fcaf347-B1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"10291","key":"2025100309090705900_fcaf347-B2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2025100309090705900_fcaf347-B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson pandemic-A call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol"},{"issue":"13","key":"2025100309090705900_fcaf347-B4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov Disord"},{"issue":"11","key":"2025100309090705900_fcaf347-B5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: A systematic analysis for the global burden of disease study 2016","volume":"17","author":"GBD","year":"2018","journal-title":"Lancet Neurol"},{"issue":"5","key":"2025100309090705900_fcaf347-B6","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2025100309090705900_fcaf347-B7","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1111\/ene.15069","article-title":"Cancer risk in Parkinson disease: An updated systematic review and meta-analysis","volume":"28","author":"Leong","year":"2021","journal-title":"Eur J Neurol"},{"issue":"6","key":"2025100309090705900_fcaf347-B8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jnci\/djq081","article-title":"Parkinson\u2019s disease and cancer: The unexplored connection","volume":"102","author":"Garber","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2025100309090705900_fcaf347-B9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s004150070171","article-title":"Mortality and cancer incidence in patients with Parkinson\u2019s disease","volume":"247","author":"Minami","year":"2000","journal-title":"J Neurol"},{"issue":"7","key":"2025100309090705900_fcaf347-B10","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.3390\/ijms25073899","article-title":"Association between Parkinson's disease and cancer: New findings and possible mediators","volume":"25","author":"Surguchov","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025100309090705900_fcaf347-B11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.parkreldis.2022.02.002","article-title":"Outcomes of gastrointestinal cancer surgeries in Parkinson\u2019s disease patients: A nationwide study","volume":"96","author":"Kodama","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2025100309090705900_fcaf347-B12","doi-asserted-by":"crossref","first-page":"105966","DOI":"10.1016\/j.parkreldis.2023.105966","article-title":"Risk of Parkinson\u2019s disease-related death in cancer survivors: A population-based study in Japan","volume":"119","author":"Hayano","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2025100309090705900_fcaf347-B13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/cam4.4457","article-title":"Incidence and relative risk of metachronous second primary cancers for 16 cancer sites, Osaka, Japan, 2000-2015: Population-based analysis","volume":"11","author":"Odani","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"2025100309090705900_fcaf347-B14","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1038\/s41598-023-30850-2","article-title":"Survival in non-small cell lung cancer patients with versus without prior cancer","volume":"13","author":"Sato","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"2025100309090705900_fcaf347-B15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jdi.13940","article-title":"Impact of coexisting diabetes on survival and risk of developing second primary cancer in diabetes patients receiving drug therapy: A multicenter retrospective cohort study of patients with cancer in Japan","volume":"14","author":"Kuwabara","year":"2023","journal-title":"J Diabetes Invest"},{"issue":"1","key":"2025100309090705900_fcaf347-B16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-022-10411-y","article-title":"Patterns of staging, treatment, and mortality in gastric, colorectal, and lung cancer among older adults with and without preexisting dementia: A Japanese multicentre cohort study","volume":"23","author":"Morishima","year":"2023","journal-title":"BMC Cancer"},{"key":"2025100309090705900_fcaf347-B17"},{"issue":"6","key":"2025100309090705900_fcaf347-B18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2025100309090705900_fcaf347-B19","first-page":"61","article-title":"Functional evaluation: The barthel index","volume":"14","author":"Mahoney","year":"1965","journal-title":"Md State Med J"},{"issue":"4","key":"2025100309090705900_fcaf347-B20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1023\/A:1011807919632","article-title":"Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson\u2019s disease","volume":"23","author":"van de Vijver","year":"2001","journal-title":"Pharm World Sci"},{"issue":"16 Pt 2","key":"2025100309090705900_fcaf347-B21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000310414.85144.ee","article-title":"Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study","volume":"70","author":"Driver","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 1","key":"2025100309090705900_fcaf347-B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/CLEP.S47150","article-title":"The impact of comorbidity on cancer survival: A review","volume":"5","author":"S\u00f8gaard","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"6","key":"2025100309090705900_fcaf347-B23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson\u2019s disease as evaluated by hoehn and yahr stage transition times","volume":"25","author":"Zhao","year":"2010","journal-title":"Mov Disord"},{"issue":"Suppl 7","key":"2025100309090705900_fcaf347-B24","first-page":"VII2","article-title":"The natural history of Parkinson\u2019s disease","volume":"253","author":"Poewe","year":"2006","journal-title":"J Neurol"},{"issue":"4","key":"2025100309090705900_fcaf347-B25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/mds.870080415","article-title":"Anxiety and motor performance in Parkinson\u2019s disease","volume":"8","author":"Siemers","year":"1993","journal-title":"Mov Disord"},{"issue":"4","key":"2025100309090705900_fcaf347-B26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00146965-200312000-00004","article-title":"Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease","volume":"16","author":"Lauterbach","year":"2003","journal-title":"Cogn Behav Neurol"},{"issue":"4","key":"2025100309090705900_fcaf347-B27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/jnp.2009.21.4.413","article-title":"Anxiety, depression, and quality of life in Parkinson\u2019s disease","volume":"21","author":"Quelhas","year":"2009","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"2025100309090705900_fcaf347-B28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/ng.491","article-title":"Somatic mutations of the Parkinson`s disease-associated gene PARK2 in glioblastoma and other human malignancies","volume":"42","author":"Veeriah","year":"2010","journal-title":"Nat Genet"},{"issue":"12","key":"2025100309090705900_fcaf347-B29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/gcc.21995","article-title":"Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN\/Parkinson's families","volume":"51","author":"Alcalay","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"36","key":"2025100309090705900_fcaf347-B30","doi-asserted-by":"crossref","first-page":"e2204835119","DOI":"10.1073\/pnas.2204835119","article-title":"Amelioration of pathologic \u03b1-synuclein-induced Parkinson's disease by irisin","volume":"119","author":"Kam","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2025100309090705900_fcaf347-B31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2025100309090705900_fcaf347-B32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1212\/WNL.0b013e31822c9123","article-title":"Neurologist care in Parkinson disease: A utilization, outcomes, and survival study","volume":"77","author":"Willis","year":"2011","journal-title":"Neurology"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf347\/64263563\/fcaf347.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/5\/fcaf347\/64263563\/fcaf347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/5\/fcaf347\/64263563\/fcaf347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:09:15Z","timestamp":1759496955000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf347\/8253753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf347","relation":{},"ISSN":["2632-1297"],"issn-type":[{"type":"electronic","value":"2632-1297"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf347"}}